Clinical Trial Update: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating post-operative T-DM1 in HER2-positive salivary gland carcinomas; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Salivary Gland Cancer, HER2 Gene Mutation | Phase 2 | Status: RECRUITING